Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients
<p>Abstract</p> <p>Background</p> <p>Despite of a growing number of gemcitabine based chemoradiotherapy studies in locally advanced pancreatic cancer (LAPC), 5-fluorouracil based regimens are still regarded to be standard and the debate of superiority between the two dr...
Main Authors: | Sauer Rolf, Brunner Thomas B, Fietkau Rainer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-07-01
|
Series: | Radiation Oncology |
Subjects: | |
Online Access: | http://www.ro-journal.com/content/6/1/88 |
Similar Items
-
Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?
by: Emilia Sawicka, et al.
Published: (2016-06-01) -
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
by: Q. P. Janssen, et al.
Published: (2021-03-01) -
Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines
by: Waisse Waissi, et al.
Published: (2021-06-01) -
Colossolactone-G synergizes the anticancer properties of 5-fluorouracil and gemcitabine against colorectal cancer cells
by: Rinad A. Algehani, et al.
Published: (2021-08-01) -
A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma—the ESO-shanghai 1 trial protocol
by: Yun Chen, et al.
Published: (2018-02-01)